Talipexole
Chemical compound
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe.
Talipexole is a dopamine D2 receptor agonist and interacts with both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.
The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints. In Japan, the Ministry of Health, Labour and Welfare mandated in 2008 that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.
01Synthesis
The N-alkylation of azepan-4-one [105416-56-6] (1) with allyl bromide in the presence of potassium carbonate gives 1-allyl-azepan-4-one (2). This is halogenated with molecular bromine in acetic acid to give 1-allyl-5-bromohexahydro-4-azepinone (3). The last step involves cyclization with thiourea (4) in refluxing ethanol, completing the synthesis of talipexole (5).
Sources and credits
This article is adapted from the Wikipedia article “Talipexole”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Talipexole-3D-balls.png by DFliyerz, CC BY-SA 3.0
- Talipexole synthesis.svg by Nuklear, CC BY-SA 4.0
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.
